As GC Biopharma successfully obtains reimbursement listing of a new product containing fenofibrate for treating hypertriglyceridemia, the industry closely watches its impact on shifting the competitive structure in the market.

Lipidil supra containing fenofibrate is a product that GC Biopharma generated as a blockbuster drug after introducing it to South Korea in 2003. However, an analysis suggests that new competition has been initiated following Abbott, the company with domestic sales rights for fenofibrate-containing products such as Lipidil supra and Lipidil-NT, changed the domestic distributor to Handok.

According to industry sources on January 8, GC Biopharma obtained reimbursement